<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01348542</url>
  </required_header>
  <id_info>
    <org_study_id>35933</org_study_id>
    <nct_id>NCT01348542</nct_id>
  </id_info>
  <brief_title>Study of Trazodone &amp; Cognitive Behavioral Therapy to Treat Insomnia</brief_title>
  <official_title>Efficacy of Trazodone vs. Cognitive Behavioral Therapy in Patients With Chronic Insomnia Associated With Objective Short Sleep Duration</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Milton S. Hershey Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Milton S. Hershey Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the effect of a 3 month medication trial of
      Trazodone versus 3 months of Cognitive Behavioral Therapy (CBT) in patients with chronic
      insomnia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Participants with chronic insomnia associated with objective short sleep duration will be
      recruited to participate in a 3 month clinical trial on the efficacy of trazodone versus CBT,
      with a 6 month follow up. The primary outcome measure will be objective sleep duration as
      measured by both actigraphy and polysomnography. The secondary outcome measure will be
      subjective severity of sleep disturbance.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 2011</start_date>
  <completion_date type="Actual">June 1, 2018</completion_date>
  <primary_completion_date type="Actual">June 1, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Objective Polysomnography Sleep Duration From Baseline to Post Treatment (3 Months)</measure>
    <time_frame>Baseline to Post Treatment (3 months)</time_frame>
    <description>Polysomnography (8 hours fixed time in bed) will be used to measure sleep duration at baseline and post treatment (3 months)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Objective Polysomnography Sleep Duration From Baseline to Follow up (9 Months)</measure>
    <time_frame>Baseline to follow up (9 months)</time_frame>
    <description>Polysomnography (8 hours fixed time in bed) will be used to measure sleep duration at baseline and follow up (9 months)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Objective Actigraphy Sleep Duration From Baseline to Post Treatment (3 Months)</measure>
    <time_frame>Baseline to Post Treatment (3 months)</time_frame>
    <description>Actigraphy (ad libitum time in bed) will be used to measure sleep duration at baseline and Post Treatment (3 months)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Objective Actigraphy Sleep Duration From Baseline to Follow up (9 Months)</measure>
    <time_frame>Baseline to follow up (9 months)</time_frame>
    <description>Actigraphy (ad libitum time in bed) will be used to measure sleep duration at baseline and follow up (9 months)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Subjective Severity of Sleep Disturbance at 3 Months</measure>
    <time_frame>Baseline to Post Treatment (3 months)</time_frame>
    <description>The Insomnia Severity Index (ISI) was used to measure the change in severity of sleep disturbance at baseline to post treatment (3 months). The ISI is composed of 7 items each rated on a scale of 0-4. The total score was calculated by adding the individual item scores. The total ISI scale score ranged from 0-28 with higher total scores indicating a higher severity of insomnia symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Subjective Severity of Sleep Disturbance at 9 Months</measure>
    <time_frame>Baseline to follow up (9 months)</time_frame>
    <description>The Insomnia Severity Index (ISI) was used to measure the change in severity of sleep disturbance at baseline to Follow Up (9 months). The ISI is composed of 7 items each rated on a scale of 0-4. The total score was calculated by adding the individual item scores. The total ISI scale score ranged from 0-28 with higher total scores indicating a higher severity of insomnia symptoms.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Insomnia</condition>
  <arm_group>
    <arm_group_label>Trazodone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cognitive Behavioral Therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trazodone</intervention_name>
    <description>50 mg once a day, for 3 months</description>
    <arm_group_label>Trazodone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Cognitive Behavioral Therapy</intervention_name>
    <description>The CBT Protocol is implemented over a period of 12 weeks, with 4 consultations held on a weekly basis and 4 held on a biweekly basis.</description>
    <arm_group_label>Cognitive Behavioral Therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Chronic insomnia with duration of more than 1 year

          -  Objective short sleep duration (&lt; 6 hours)

          -  BMI &lt; 39

          -  Ages 30-60

          -  Men &amp; Women

        Exclusion Criteria:

          -  Major Mental Illness

          -  Substance Abuse/Dependence

          -  Sleep Apnea

          -  Periodic Limb Movement Disorder

          -  Shift Work or circadian disorders

          -  Diabetes

          -  Chronic Renal Failure, Hepatic Insufficiency, Chronic Heart Failure

          -  Current Use of hypnotics or sleep inducing sedative antidepressants
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alexandros N Vgontzas, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Penn State College of Medicine, Penn State Milton S. Hershey Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Penn State College of Medicine, Penn State Milton S. Hershey Medical Center</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Vgontzas AN, Liao D, Pejovic S, Calhoun S, Karataraki M, Basta M, Fern√°ndez-Mendoza J, Bixler EO. Insomnia with short sleep duration and mortality: the Penn State cohort. Sleep. 2010 Sep;33(9):1159-64.</citation>
    <PMID>20857861</PMID>
  </reference>
  <reference>
    <citation>Vgontzas AN, Liao D, Pejovic S, Calhoun S, Karataraki M, Bixler EO. Insomnia with objective short sleep duration is associated with type 2 diabetes: A population-based study. Diabetes Care. 2009 Nov;32(11):1980-5. doi: 10.2337/dc09-0284. Epub 2009 Jul 29.</citation>
    <PMID>19641160</PMID>
  </reference>
  <reference>
    <citation>Vgontzas AN, Liao D, Bixler EO, Chrousos GP, Vela-Bueno A. Insomnia with objective short sleep duration is associated with a high risk for hypertension. Sleep. 2009 Apr;32(4):491-7.</citation>
    <PMID>19413143</PMID>
  </reference>
  <reference>
    <citation>Vgontzas AN, Bixler EO, Lin HM, Prolo P, Mastorakos G, Vela-Bueno A, Kales A, Chrousos GP. Chronic insomnia is associated with nyctohemeral activation of the hypothalamic-pituitary-adrenal axis: clinical implications. J Clin Endocrinol Metab. 2001 Aug;86(8):3787-94.</citation>
    <PMID>11502812</PMID>
  </reference>
  <reference>
    <citation>Fernandez-Mendoza J, Calhoun S, Bixler EO, Pejovic S, Karataraki M, Liao D, Vela-Bueno A, Ramos-Platon MJ, Sauder KA, Vgontzas AN. Insomnia with objective short sleep duration is associated with deficits in neuropsychological performance: a general population study. Sleep. 2010 Apr;33(4):459-65.</citation>
    <PMID>20394314</PMID>
  </reference>
  <reference>
    <citation>Fernandez-Mendoza J, Calhoun SL, Bixler EO, Karataraki M, Liao D, Vela-Bueno A, Jose Ramos-Platon M, Sauder KA, Basta M, Vgontzas AN. Sleep misperception and chronic insomnia in the general population: role of objective sleep duration and psychological profiles. Psychosom Med. 2011 Jan;73(1):88-97. doi: 10.1097/PSY.0b013e3181fe365a. Epub 2010 Oct 26.</citation>
    <PMID>20978224</PMID>
  </reference>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>April 20, 2011</study_first_submitted>
  <study_first_submitted_qc>May 4, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 5, 2011</study_first_posted>
  <results_first_submitted>May 28, 2019</results_first_submitted>
  <results_first_submitted_qc>May 28, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">June 21, 2019</results_first_posted>
  <last_update_submitted>February 14, 2020</last_update_submitted>
  <last_update_submitted_qc>February 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 25, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Milton S. Hershey Medical Center</investigator_affiliation>
    <investigator_full_name>Alexandros Vgontzas</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Chronic Insomnia</keyword>
  <keyword>Short Sleep Duration</keyword>
  <keyword>Trazodone</keyword>
  <keyword>Cognitive Behavioral Therapy</keyword>
  <keyword>Efficacy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sleep Initiation and Maintenance Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Trazodone</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>January 3, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/42/NCT01348542/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Trazodone</title>
          <description>Trazodone: 50 mg once a day, for 3 months</description>
        </group>
        <group group_id="P2">
          <title>Cognitive Behavioral Therapy</title>
          <description>Cognitive Behavioral Therapy: The CBT Protocol is implemented over a period of 12 weeks, with 4 consultations held on a weekly basis and 4 held on a biweekly basis.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Trazodone</title>
          <description>Trazodone: 50 mg once a day, for 3 months</description>
        </group>
        <group group_id="B2">
          <title>Cognitive Behavioral Therapy</title>
          <description>Cognitive Behavioral Therapy: The CBT Protocol is implemented over a period of 12 weeks, with 4 consultations held on a weekly basis and 4 held on a biweekly basis.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
            <count group_id="B2" value="11"/>
            <count group_id="B3" value="21"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="21"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42.6" spread="8.75"/>
                    <measurement group_id="B2" value="45.27" spread="9.94"/>
                    <measurement group_id="B3" value="44.0" spread="9.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Insomnia Severity Index</title>
          <description>The Insomnia Severity Index (ISI) a self completed questionnaire was used to measure the severity of sleep disturbance. The ISI is composed of 7 items each rated on a scale of 0-4. The total score was calculated by adding the individual item scores. The total ISI Scale can range from 0-28 with higher total scores indicating a higher severity of insomnia symptoms and sleep disturbance.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16.70" spread="3.59"/>
                    <measurement group_id="B2" value="16.18" spread="2.18"/>
                    <measurement group_id="B3" value="16.43" spread="2.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Objective Polysomnography Sleep Duration From Baseline to Post Treatment (3 Months)</title>
        <description>Polysomnography (8 hours fixed time in bed) will be used to measure sleep duration at baseline and post treatment (3 months)</description>
        <time_frame>Baseline to Post Treatment (3 months)</time_frame>
        <population>Objective Short Sleepers defined by 2 week actigraphy sleep duration measurement</population>
        <group_list>
          <group group_id="O1">
            <title>Trazodone</title>
            <description>Trazodone: 50 mg once a day, for 3 months</description>
          </group>
          <group group_id="O2">
            <title>Cognitive Behavioral Therapy</title>
            <description>Cognitive Behavioral Therapy: The CBT Protocol is implemented over a period of 12 weeks, with 4 consultations held on a weekly basis and 4 held on a biweekly basis.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Objective Polysomnography Sleep Duration From Baseline to Post Treatment (3 Months)</title>
          <description>Polysomnography (8 hours fixed time in bed) will be used to measure sleep duration at baseline and post treatment (3 months)</description>
          <population>Objective Short Sleepers defined by 2 week actigraphy sleep duration measurement</population>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.95" spread="31.70"/>
                    <measurement group_id="O2" value="38.91" spread="24.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Objective Polysomnography Sleep Duration From Baseline to Follow up (9 Months)</title>
        <description>Polysomnography (8 hours fixed time in bed) will be used to measure sleep duration at baseline and follow up (9 months)</description>
        <time_frame>Baseline to follow up (9 months)</time_frame>
        <population>From the 21 participants who completed the study, 15 met the criteria for objective short sleep duration and were included in the final analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Trazodone</title>
            <description>Trazodone: 50 mg once a day, for 3 months</description>
          </group>
          <group group_id="O2">
            <title>Cognitive Behavioral Therapy</title>
            <description>Cognitive Behavioral Therapy: The CBT Protocol is implemented over a period of 12 weeks, with 4 consultations held on a weekly basis and 4 held on a biweekly basis.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Objective Polysomnography Sleep Duration From Baseline to Follow up (9 Months)</title>
          <description>Polysomnography (8 hours fixed time in bed) will be used to measure sleep duration at baseline and follow up (9 months)</description>
          <population>From the 21 participants who completed the study, 15 met the criteria for objective short sleep duration and were included in the final analysis.</population>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.78" spread="76.39"/>
                    <measurement group_id="O2" value="32.36" spread="30.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Objective Actigraphy Sleep Duration From Baseline to Post Treatment (3 Months)</title>
        <description>Actigraphy (ad libitum time in bed) will be used to measure sleep duration at baseline and Post Treatment (3 months)</description>
        <time_frame>Baseline to Post Treatment (3 months)</time_frame>
        <population>From the 21 participants who completed the study, 15 met the criteria for objective short sleep duration and were included in the final analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Trazodone</title>
            <description>Trazodone: 50 mg once a day, for 3 months</description>
          </group>
          <group group_id="O2">
            <title>Cognitive Behavioral Therapy</title>
            <description>Cognitive Behavioral Therapy: The CBT Protocol is implemented over a period of 12 weeks, with 4 consultations held on a weekly basis and 4 held on a biweekly basis.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Objective Actigraphy Sleep Duration From Baseline to Post Treatment (3 Months)</title>
          <description>Actigraphy (ad libitum time in bed) will be used to measure sleep duration at baseline and Post Treatment (3 months)</description>
          <population>From the 21 participants who completed the study, 15 met the criteria for objective short sleep duration and were included in the final analysis.</population>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.01" spread="57.50"/>
                    <measurement group_id="O2" value="-11.73" spread="31.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Objective Actigraphy Sleep Duration From Baseline to Follow up (9 Months)</title>
        <description>Actigraphy (ad libitum time in bed) will be used to measure sleep duration at baseline and follow up (9 months)</description>
        <time_frame>Baseline to follow up (9 months)</time_frame>
        <population>From the 21 participants who completed the study, 15 met the criteria for objective short sleep duration and were included in the final analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Trazodone</title>
            <description>Trazodone: 50 mg once a day, for 3 months</description>
          </group>
          <group group_id="O2">
            <title>Cognitive Behavioral Therapy</title>
            <description>Cognitive Behavioral Therapy: The CBT Protocol is implemented over a period of 12 weeks, with 4 consultations held on a weekly basis and 4 held on a biweekly basis.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Objective Actigraphy Sleep Duration From Baseline to Follow up (9 Months)</title>
          <description>Actigraphy (ad libitum time in bed) will be used to measure sleep duration at baseline and follow up (9 months)</description>
          <population>From the 21 participants who completed the study, 15 met the criteria for objective short sleep duration and were included in the final analysis.</population>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.35" spread="27.47"/>
                    <measurement group_id="O2" value="-7.56" spread="38.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Subjective Severity of Sleep Disturbance at 3 Months</title>
        <description>The Insomnia Severity Index (ISI) was used to measure the change in severity of sleep disturbance at baseline to post treatment (3 months). The ISI is composed of 7 items each rated on a scale of 0-4. The total score was calculated by adding the individual item scores. The total ISI scale score ranged from 0-28 with higher total scores indicating a higher severity of insomnia symptoms.</description>
        <time_frame>Baseline to Post Treatment (3 months)</time_frame>
        <population>From the 21 participants who completed the study, 15 met the criteria for objective short sleep duration and were included in the final analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Trazodone</title>
            <description>Trazodone: 50 mg once a day, for 3 months</description>
          </group>
          <group group_id="O2">
            <title>Cognitive Behavioral Therapy</title>
            <description>Cognitive Behavioral Therapy: The CBT Protocol is implemented over a period of 12 weeks, with 4 consultations held on a weekly basis and 4 held on a biweekly basis.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Subjective Severity of Sleep Disturbance at 3 Months</title>
          <description>The Insomnia Severity Index (ISI) was used to measure the change in severity of sleep disturbance at baseline to post treatment (3 months). The ISI is composed of 7 items each rated on a scale of 0-4. The total score was calculated by adding the individual item scores. The total ISI scale score ranged from 0-28 with higher total scores indicating a higher severity of insomnia symptoms.</description>
          <population>From the 21 participants who completed the study, 15 met the criteria for objective short sleep duration and were included in the final analysis.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.29" spread="4.35"/>
                    <measurement group_id="O2" value="-10.75" spread="2.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Subjective Severity of Sleep Disturbance at 9 Months</title>
        <description>The Insomnia Severity Index (ISI) was used to measure the change in severity of sleep disturbance at baseline to Follow Up (9 months). The ISI is composed of 7 items each rated on a scale of 0-4. The total score was calculated by adding the individual item scores. The total ISI scale score ranged from 0-28 with higher total scores indicating a higher severity of insomnia symptoms.</description>
        <time_frame>Baseline to follow up (9 months)</time_frame>
        <population>From the 21 participants who completed the study, 15 met the criteria for objective short sleep duration and were included in the final analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Trazodone</title>
            <description>Trazodone: 50 mg once a day, for 3 months</description>
          </group>
          <group group_id="O2">
            <title>Cognitive Behavioral Therapy</title>
            <description>Cognitive Behavioral Therapy: The CBT Protocol is implemented over a period of 12 weeks, with 4 consultations held on a weekly basis and 4 held on a biweekly basis.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Subjective Severity of Sleep Disturbance at 9 Months</title>
          <description>The Insomnia Severity Index (ISI) was used to measure the change in severity of sleep disturbance at baseline to Follow Up (9 months). The ISI is composed of 7 items each rated on a scale of 0-4. The total score was calculated by adding the individual item scores. The total ISI scale score ranged from 0-28 with higher total scores indicating a higher severity of insomnia symptoms.</description>
          <population>From the 21 participants who completed the study, 15 met the criteria for objective short sleep duration and were included in the final analysis.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.29" spread="3.77"/>
                    <measurement group_id="O2" value="-10.38" spread="3.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>9 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Trazodone</title>
          <description>Trazodone: 50 mg once a day, for 3 months</description>
        </group>
        <group group_id="E2">
          <title>Cognitive Behavioral Therapy</title>
          <description>Cognitive Behavioral Therapy: The CBT Protocol is implemented over a period of 12 weeks, with 4 consultations held on a weekly basis and 4 held on a biweekly basis.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Alexandros Vgontzas</name_or_title>
      <organization>Penn State University College of Medicine</organization>
      <phone>717 531-7278</phone>
      <email>vgontzas@pennstatehealth.psu.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

